Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

VACCELERATE

Financiado

Cerrado

VACCELERATE European Corona Vaccine Trial Accelerator Platform

The ongoing COVID-19 pandemic creates an unprecedented burden worldwide. Vaccine-induced immunity is the only promising solution. There is continued need for phase 2 & 3 vaccine trials to reach long-term, large-scale immunity of t... ver más

27/01/2024

KLINIKUM DER UNIVE...

26M€

Presupuesto del proyecto: 26M€

Líder del proyecto

KLINIKUM DER UNIVERSITAET ZU KOELN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 36 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2024-01-27 No tenemos la información de la convocatoria

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

36 Participantes

KLINIKUM DER UNIVERSITAET ZU...

7.88M€ | Lider

GABANDE

329.25K€ | Participante

BIOMEDICAL RESEARCH CENTER O...

92.36K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

TRANSVAC European Network of Vaccine Development and Research 12M€ Cerrado

EU-RESPONSE European Research and Preparedness Network for Pandemics and... 16M€ Cerrado

INCENTIVE Indo European Consortium for Next Generation Influenza Vacci... 20M€ Cerrado

ORCHESTRA Connecting European Cohorts to Increase Common and Effective... 30M€ Cerrado

EBOVAC1 Development of a Prophylactic Ebola Vaccine Using an Heterol... 98M€ Cerrado

END-VOC ENDING COVID 19 VARIANTS OF CONCERN THROUGH COHORT STUDIES:... 10M€ Cerrado

Duración del proyecto: 35 meses Fecha Inicio: 2021-02-17
Fecha Fin: 2024-01-27

Líder del proyecto

KLINIKUM DER UNIVERSITAET ZU KOELN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 26M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The ongoing COVID-19 pandemic creates an unprecedented burden worldwide. Vaccine-induced immunity is the only promising solution. There is continued need for phase 2 & 3 vaccine trials to reach long-term, large-scale immunity of the entire European population. VACCELERATE will be the pan-European backbone accelerating phase 2 & 3 COVID-19 vaccine trials. The overall objective of VACCELERATE is to connect all European stakeholders involved in vaccine development to provide a pan-European platform for clinical trial design and conduct. VACCELERATE constitutes the rapid response single entry-point to stakeholders from public health authorities to vaccine developers, to address respective needs and kick-start specifically phase 2 & 3 vaccine trials. VACCELERATE conducts capacity mapping of clinical trial and laboratory sites to identify suitable sites for individual phase 2 & 3 vaccine trials. Capacity building via training will increase quality in sites across Europe. Volunteer registries facilitate patient recruitment. Access to laboratory sites and a standardised set of assays essential for clinical phase 2 & 3 trials is provided. A harmonised European approach to vaccine trials is enabled by aligning educational standards, coordination of laboratory support and providing standardised assays and trial protocols. Harmonised data collection, open data sharing and pooling of data for stronger analysis enables data standardisation. VACCELERATE offers solutions for characteristic vaccine development issues during pandemics by closing gaps in public health knowledge and improving knowledge transfer. VACCELERATE amalgamates the vast but scattered expertise across Europe into one network to deliver strategic scientific leadership and guidance on vaccine trials in Europe. Beyond the COVID-19 pandemic, it will be an established pandemic preparedness network, ready to face emerging future pandemics, as well as a pivot in Europe?s capacity to develop vaccines.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores